The present technology relates to interatrial shunting systems and methods. In some embodiments, the present technology includes interatrial shunting systems that include a shunting element having a lumen extending therethrough that is configured to fluidly couple the left atrium and the right atrium when the shunting element is implanted in a patient. The system can also include an energy receiving component for receiving energy from an energy source positioned external to the body, an energy storage component for storing the received energy, and/or a flow control mechanism for adjusting a geometry of the lumen.

A puncture needle can comprise a puncture tip configured to pierce tissue, and a distal portion comprising an anchor portion and a curved puncture portion. The curved puncture portion can comprise a first end associated with the puncture tip and a second end coupled to the anchor portion, where the anchor portion comprises a portion distal of the curved puncture portion. A puncture needle system can comprise the puncture needle and a delivery catheter comprising a lumen, the puncture needle extending through the lumen. The delivery catheter can have a side outlet opening on a distal portion of the delivery catheter configured to allow extension therethrough of at least a portion of the curved puncture portion, where the anchor portion extends through a portion of the lumen distal of the side outlet opening.

A system and method of unloading a heart chamber is described. The chamber can be a ventricle and the system can unload the ventricle during or after a heart attack. The ventricular unloading system includes a transthoracic needle insertable into the ventricle, a vascular access cannula insertable into a blood vessel, and a pump to move blood from the ventricle to the blood vessel through the transthoracic needle and the vascular access cannula. The ventricular unloading system can be used by an emergency medical technician in a non-hospital setting. Accordingly, the ventricular unloading system can provide early protection against infarct to improve clinical outcomes for a patient. Other embodiments are also described and claimed.

Methods and devices that prevent stasis in the LAA by either increasing the flow through the LAA or by closing off or sealing the LAA. Increasing the flow is accomplished through shunts, flow diverters, agitators, or by increasing the size of the ostium. Closing off the LAA is accomplished using seals or by cinching the LAA.

The embodiments described herein relate to a self-positioning, quick-deployment low profile transvenous electrode system for sequentially pacing both the atrium and ventricle of the heart in the “dual chamber” mode, and methods for deploying the same.

An implantable anastomotic assembly, which is configured to be attached to cardiovascular tissue, includes a connection interface, a plurality of outer plates, and a plurality of connectors configured to extend between and interconnect the connection interface and the plurality of outer plates, respectively, according to various embodiments. The connection interface is separate from and non-contiguous with the plurality of outer plates, according to various embodiments.

The present technology relates to interatrial shunting systems and methods. In some embodiments, the present technology includes a system for shunting blood between a left atrium and a right atrium of a patient. The system can include a shunting element having a lumen extending therethrough. The lumen is configured to fluidly couple the left atrium and the right atrium when the shunting element is implanted in the patient. The system can also include a sensor configured to be implanted in the patient and operably coupled to the shunting element. An actuation element is coupled to the sensor. The actuation element is configured to be selectively energized and transmit a desired motion to the sensor to reduce the likelihood of tissue ingrowth/overgrowth and adhesion on at least a portion of the sensor.

Systems for delivering a device for regulating blood pressure across a patients atrial septum are provided. The delivery apparatus may include a first catheter, a hub having one or more engagers disposed thereon, the one or more engagers configured to releasably engage with a first expandable end of the shunt in a contracted delivery state within a lumen of a sheath, and an second catheter extending through a center lumen of the first catheter and the hub, wherein the first catheter, the hub, and the second catheter are independently moveable relative to the sheath. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices also may be used to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

The present invention relates to a targeted cardiac therapy device that can precisely deliver therapeutic compounds to desired locations on, around or within the heart of a patient, and methods of treating conduction system disease, sinus node dysfunction, atrial fibrillation, myocardial infarction, heart failure, and muscular diseases with cardiac involvement, using the described devices to deliver genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals and biologics.

Left atrial appendage (LAA) occlusion device including a membrane, a plurality of fixation splines and a deployment hub, the plurality of fixation splines for affixing the LAA occlusion device to an ostium of the LAA, the deployment hub being positioned in the membrane, the deployment hub including a threaded aperture and a one-way valve, for enabling a toxin to be entered into the LAA through the deployment hub.